Most Read Articles
Roshini Claire Anthony, 19 Jan 2018

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

01 Jun 2016
Fluticasone furoate is superior to mometasone nasal spray in improving several perceived sensory attributes of allergic rhinitis patients, based on a multicentre, randomised, crossover, prospective study.
01 Aug 2014
Bilastine demonstrated high efficacy in the treatment of patients with allergic rhinitis, based on an analysis of publications.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Efficacy of dual bronchodilators therapy and inhaler devices for COPD management - can ANORO® help your COPD patients?

04 Aug 2017
Dato' Dr Hj Abdul Razak Abdul Muttalif

Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD.
At a recent expert discussion during the Malaysian Thoracic Society (MTS) Congress 2017, Dato' Dr Abdul Razak Abdul Muttalif and Dr Ahmad Izuanuddin provided insights on the current landscape of COPD in Malaysia and the role of dual bronchodilators such as umeclidinium/vilanterol in the management of COPD. Find out more about the use of ANORO® in the treatment of COPD in our upcoming symposium highlight article. 

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 19 Jan 2018

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

01 Jun 2016
Fluticasone furoate is superior to mometasone nasal spray in improving several perceived sensory attributes of allergic rhinitis patients, based on a multicentre, randomised, crossover, prospective study.
01 Aug 2014
Bilastine demonstrated high efficacy in the treatment of patients with allergic rhinitis, based on an analysis of publications.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.